Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.45 |
| ▸ | SLC5A2 | P31639 | 18/20 | 0.42 |
| ▸ | SLC5A1 | P13866 | 11/20 | 0.40 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17866099 | 0.94 | SLC28A3 (0.41) | SLC28A3SLC5A2SLC5A1 | |
| SCHEMBL22717169 | 0.94 | SLC28A3 (0.51) | SLC28A3SLC5A2SLC5A1HDAC1 | |
| SCHEMBL4001695 | 0.88 | SLC28A3 (0.59) | SLC28A3SLC5A2SLC5A1HDAC1 | |
| SCHEMBL4001687 | 0.88 | SLC28A3 (0.59) | SLC28A3SLC5A2SLC5A1HDAC1 | |
| SCHEMBL4361428 | 0.87 | SLC5A2 (0.48) | SLC5A2SLC5A1 | |
| SCHEMBL4010809 | 0.81 | SLC5A2 (0.55) | SLC28A3SLC5A2SLC5A1 | |
| SCHEMBL4010805 | 0.81 | SLC5A2 (0.55) | SLC28A3SLC5A2SLC5A1 | |
| SCHEMBL4000120 | 0.74 | SLC5A2 (0.64) | SLC5A2SLC5A1 | |
| SCHEMBL4000126 | 0.74 | SLC5A2 (0.64) | SLC5A2SLC5A1 | |
| SCHEMBL10795670 | 0.71 | SLC5A2 (0.52) | SLC5A2SLC5A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1782828-B1 | PROGRESSION INHIBITOR FOR DISEASE ATTRIBUTED TO ABNORMAL ACCUMULATION OF LIVER FAT | KISSEI PHARMACEUTICAL (JP) | 2016-06-29 | — | — | EP | disclosed |
| US-8951976-B2 | Progression inhibitor for disease attributed to abnormal accumulation of liver fat | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2015-02-10 | — | — | US | disclosed |
| US-20090286751-A1 | PROGRESSION INHIBITOR FOR DISEASE ATTRIBUTED TO ABNORMAL ACCUMULATION OF LIVER FAT | KISSEI PHARMACEUTICAL CO., LTD. (JP) | 2009-11-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090286751-A1 | PROGRESSION INHIBITOR FOR DISEASE ATTRIBUTED TO ABNORMAL ACCUMULATION OF LIVER FAT | FABP1, SLC2A1, SLC10A1 | SLC28A3 59/4885SLC5A2 11/4885SLC5A1 15/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.